130 related articles for article (PubMed ID: 38314790)
1. Relationship between earlier introduction of tocilizumab and glucocorticoid-sparing effects on the acute phase of adult-onset Still's disease.
Yoshihara R; Tsuchiya H; Shoda H; Fujio K
Scand J Rheumatol; 2024 Jul; 53(4):284-287. PubMed ID: 38314790
[No Abstract] [Full Text] [Related]
2. Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial.
Kaneko Y; Kameda H; Ikeda K; Ishii T; Murakami K; Takamatsu H; Tanaka Y; Abe T; Takeuchi T
Ann Rheum Dis; 2018 Dec; 77(12):1720-1729. PubMed ID: 30279267
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety of tocilizumab treatment on chronic active hepatitis C in a patient with adult onset Still's disease.
Forestier E; Pasquali JL
Joint Bone Spine; 2015 Mar; 82(2):136-7. PubMed ID: 25553837
[No Abstract] [Full Text] [Related]
4. Efficacy of Low-Dose Tocilizumab on Relapsing Adult-Onset Still's Disease.
Vandemergel X; Vandergheynst F
Acta Medica (Hradec Kralove); 2016; 59(1):22-5. PubMed ID: 27131353
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of sarilumab in adult-onset Still's disease as a corticosteroid-sparing agent.
Simeni Njonnou SR; Soyfoo MS; Vandergheynst FA
Rheumatology (Oxford); 2019 Oct; 58(10):1878-1879. PubMed ID: 31056689
[No Abstract] [Full Text] [Related]
6. Biomarkers for disease flare in patients with adult-onset Still's disease undergoing treatment with tocilizumab.
Yamada H; Kaneko Y; Tamai H; Takeuchi T
Rheumatology (Oxford); 2020 Feb; 59(2):440-442. PubMed ID: 31504968
[No Abstract] [Full Text] [Related]
7. Optimal time of starting tocilizumab in acute phase of adult-onset Still's disease and comparison of its efficacy with that of methotrexate: a case series and a review of the literature.
Suzuki S; Kataoka Y; Otani T; Taniguchi Y; Ikeda K; Tamura N; Morimoto S
Clin Rheumatol; 2024 Mar; 43(3):1245-1251. PubMed ID: 38342797
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of tocilizumab in refractory adult-onset Still's disease; report of 2 cases.
Andrade-Ortega L; Irazoque-Palazuelos F; Muñoz-López S; Rosales-Don Pablo VM
Reumatol Clin; 2014; 10(3):199-200. PubMed ID: 24076178
[No Abstract] [Full Text] [Related]
9. Tocilizumab in adult-onset Still's disease: the Israeli experience.
Elkayam O; Jiries N; Dranitzki Z; Kivity S; Lidar M; Levy O; Ablin J; Abu-Shakra M; Savargyl-Maman H; Padova H; Caspi D; Rosner I
J Rheumatol; 2014 Feb; 41(2):244-7. PubMed ID: 24429168
[TBL] [Abstract][Full Text] [Related]
10. Prolonged treatment with Tadekinig alfa in adult-onset Still's disease.
Kiltz U; Kiefer D; Braun J; Schiffrin EJ; Girard-Guyonvarc'h C; Gabay C
Ann Rheum Dis; 2020 Jan; 79(1):e10. PubMed ID: 30352887
[No Abstract] [Full Text] [Related]
11. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease.
Bannai E; Yamashita H; Kaneko S; Ueda Y; Ozaki T; Tsuchiya H; Takahashi Y; Kaneko H; Kano T; Mimori A
Mod Rheumatol; 2016; 26(2):297-301. PubMed ID: 24697199
[TBL] [Abstract][Full Text] [Related]
12. [Tocilizumab effectiveness in adult Still's disease].
López Buitrago R; Estrada Dorronsoro S; Cervera Segura R; Espinosa Garriga G
Med Clin (Barc); 2012 Jan; 138(1):42-3. PubMed ID: 21605875
[No Abstract] [Full Text] [Related]
13. Successful treatment with tocilizumab in a patient with refractory adult-onset Still's disease (AOSD).
Yoshimura M; Makiyama J; Koga T; Miyashita T; Izumi Y; Torigoshi T; Motokawa S; Eguchi K; Migita K
Clin Exp Rheumatol; 2010; 28(1):141-2. PubMed ID: 20346255
[No Abstract] [Full Text] [Related]
14. A SEVERE CASE OF ADULT ONSET STILLS DISEASE WITH MYOPERICARDITIS, RESISTANT TO TREATMENT WITH TOCILIZUMAB BUT RESPONSIVE TO ANAKINRA.
Waghmare S; Valecka B; Cairns AP
Ulster Med J; 2015 May; 84(2):130-2. PubMed ID: 26376493
[No Abstract] [Full Text] [Related]
15. The effect of tocilizumab on preventing relapses in adult-onset Still's disease: A retrospective, single-center study.
Nishina N; Kaneko Y; Kameda H; Takeuchi T
Mod Rheumatol; 2015 May; 25(3):401-4. PubMed ID: 25401229
[TBL] [Abstract][Full Text] [Related]
16. Urticarial rash, fever, and arthritis: A case of refractory Adult-onset Still's disease with good response to tocilizumab.
Wawrzycki B; Krasowska D; Pietrzak A; Wielosz E; Majdan M; Lotti T
Dermatol Ther; 2019 Sep; 32(5):e13041. PubMed ID: 31361930
[TBL] [Abstract][Full Text] [Related]
17. Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.
Kalliolias GD; Georgiou PE; Antonopoulos IA; Andonopoulos AP; Liossis SN
Ann Rheum Dis; 2007 Jun; 66(6):842-3. PubMed ID: 17513574
[No Abstract] [Full Text] [Related]
18. Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence.
de Boysson H; Février J; Nicolle A; Auzary C; Geffray L
Clin Rheumatol; 2013 Jan; 32(1):141-7. PubMed ID: 23108887
[TBL] [Abstract][Full Text] [Related]
19. Canakinumab in a case of adult onset still's disease: efficacy only on systemic manifestations.
Lo Gullo A; Caruso A; Pipitone N; Macchioni P; Pazzola G; Salvarani C
Joint Bone Spine; 2014 Jul; 81(4):376-7. PubMed ID: 24462130
[No Abstract] [Full Text] [Related]
20. Two cases of adult-onset Still's disease treated with tocilizumab that achieved tocilizumab-free remission.
Kobayashi D; Ito S; Murasawa A; Narita I; Nakazono K
Intern Med; 2015; 54(20):2675-9. PubMed ID: 26466710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
